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K e y  M e s s a g e s 
1. A state-transition Markov model was used to 
evaluate various interventions across different 
breast cancer stages based on the generalised 
cost-effectiveness analysis.
2. From all strategies considered, the optimal 
allocation of additional resources for breast 
cancer in descending order would be: 25% 
reduction in waiting time for postoperative 
radiotherapy (average cost-effectiveness ratio, 
US$5000 per quality-adjusted life year [QALY]); 
enhanced, home-based palliative care (US$7105 
per QALY); adjuvant, sequential endocrine 
therapy (US$17 963 per QALY); targeted 
immunotherapy (US$62 092 per QALY); and 
Generalised cost-effectiveness analysis for 
breast cancer prevention and care in Hong Kong 
Chinese
Introduction
Decisions on funding for interventions at different 
stages of specific conditions have often been made 
in isolation. For diseases such as breast cancer, 
budgetary allocation was proposed to be set at a 
higher level, given the local disease burden. We 
have used generalised cost-effectiveness analysis 
(GCEA)1 to compare alternative breast cancer-
related interventions throughout the disease course.2 
In the context of the Hong Kong public health 
care system, this study determined the optimal 
combination of screening, enhanced capacity for 
postoperative radiotherapy, adjuvant hormonal 
therapy with aromatase inhibitors (AIs), and targeted 
immunotherapy with trastuzumab (herceptin) [that 
has been excluded from the standard drug formulary 
in the public sector], and enhanced palliative services 
in order to maximise overall clinical benefits, subject 
to the constraints of a limited budget.
Methods
This study was conducted from September 2011 
to August 2012. Data were extracted from local 
clinical, epidemiology and economic data, the 
US Surveillance, Epidemiology, and End Results 
database, and the literature and expert opinion 
whenever appropriate. Clinical effectiveness data 
from several breast cancer trials including the 
Early Breast Cancer Trialists’ Collaborative Group 
overview of tamoxifen, the ATAC trial, and other 
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primary breast cancer trials including NSABP (trial 
B-31), NCCTG (trial N9831), HERA, and BCIRG 
(trial 006) were also used. Cost data were derived 
mostly from local sources such as the government 
gazette (public fees and charges) and publications of 
the Hospital Authority (patient-related group costs). 
To verify internal and external data consistency, 
the derived cost estimates were benchmarked with 
relevant overseas’ data. 
 Based on our previous decision analytic model 
for the clinical course of breast cancer for Hong 
Kong Chinese women (Fig 1),3 the GCEA evaluated 
various interventions across different stages of 
breast cancer. The costs and benefits of alternative 
strategies were considered throughout the disease 
pathway (Fig 2). To identify the full range of possible 
interventions throughout the disease course, the 
literature on prevention and care of breast cancer 
appropriate for implementation in Hong Kong was 
reviewed. Relevancy of associated data to support a 
cost-effectiveness analysis was also considered. 
 Strategies studied were: (1) biennial 
mammography for women aged 40 to 69 or 79 years, 
(2) reduction in waiting time for postoperative 
radiotherapy by 15% or 25%, (3) neo-adjuvant 
treatment using newer and more expensive 
hormonal modulators AIs (such as anastrozole, 
letrozole, and exemestane) for postmenopausal 
hormonal-sensitive patients (upfront AI therapy 
or sequentially/switching with tamoxifen and AI), 
(4) targeted trastuzumab immunotherapeutics (ie 
HEALTH AND HEALTH SERVICES RESEARCH FUND
mass mammography screening for women aged 
40 to 69 years (US$72 576 per QALY).
3.  The generalised cost-effectiveness analysis for the 
full range of interventions for the same disease 
enables rational prioritisation and coherent 
allocation of resources.
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herceptin) for breast cancer patients with HER2 over-
expression, and (5) enhanced home- or inpatient-
based palliative services. The current standard 
and protocol of care as per the Hospital Authority 
(with comparably high international standards in 
management and patient care) was the comparator. 
Model parameters and assumptions were based 
on best available data including local clinical, 
epidemiological, and economic data, as well as a 
comprehensive literature review. The costs, quality-
adjusted life years (QALYs) saved, and average cost-
effectiveness ratios of all strategies were compared. 
Budgetary thresholds were benchmarked against 
hypothetical scenarios of different funding levels. 
Guidelines from the World Health Organization’s 
WHO-CHOICE programme1 were followed. 
 Five main direct medical costs were considered: 
(1) mammography screening, (2) evaluation of 
abnormal screens, (3) initial treatment of ductal 
carcinoma in situ and invasive cancer including 
diagnostic tests, procedures, surgery, drugs (standard 
formulary inclusive of tamoxifen), outpatient 
visits, and hospitalisation, (4) adjuvant hormonal 
AI therapy and immunotherapeutics (including 
trastuzumab, HercepTest, and FISH testing for 
HER2 expression, and cardiac monitoring), and (5) 
terminal care during the last 6 months of life. Other 
major non–health care costs were also considered 
such as transportation and time costs. All costs were 
adjusted to the 2010 level.
FIG 1.  Health states and transitions, adopted from Wong et al, 20073
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FIG 2.  Decision tree of breast cancer–related interventions*
*	 BCS	denotes	breast-conserving	surgery,	AI	aromatase	inhibitor,	ER+	oestrogen	receptor	positive,	BrCA	breast	cancer,	and	HER2+	over-expres-
sion	of	human	epidermal	growth	factor	receptor	2
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(2) Shortening interval from BCS to radiotherapy
(3) Adjuvant endocrine therapy for post-menopausal ER+ BrCA
(4) Trastuzumab use for 1 year in HER2+ BrCA
(5) Enhanced palliative services in advanced BrCA stage
Hong Kong Med J  ⎥  Volume 21 Number 6 (Supplement 6)  ⎥  December 2015  ⎥  www.hkmj.org
#  Generalised cost-effectiveness of breast cancer prevention and care  # 
11Hong Kong Med J  ⎥  Volume 21 Number 6 (Supplement 6)  ⎥  December 2015  ⎥  www.hkmj.org
 In the GCEA, the performance of alternative 
options of the same class of interventions (eg mass 
biennial screening for women aged 40 to 69 years vs 
79 years) was first assessed under a ‘competing choice’ 
framework using the incremental cost-effectiveness 
ratio (ICER). Strategies that were less effective and 
more costly than an alternative strategy (strongly 
dominated) and strategies that had a higher ICER 
than a more effective alternative strategy (weakly 
dominated) were eliminated. This process was 
repeated for all classes of intervention where more 
than one alternative was considered. All strategies 
that remained from different classes of interventions 
were entered into a generalised league table and 
compared based on their average cost-effectiveness 
ratios. Independent interventions can be added to 
existing interventions, whereas mutually exclusive 
interventions must replace an existing intervention. 
Results of the interventions were then rank-ordered 
by their average cost-effectiveness ratios in the same 
league table.
 Detailed clinical data, parameters, and model 
assumptions have been reported.2 A societal 
perspective was adopted in the analyses. Future 
costs and QALYs were discounted at a rate of 3% per 
year. 
 A probabilistic sensitivity analysis was 
conducted to examine uncertainty surrounding 
choice of policy. Clinical and cost parameters were 
specified with appropriate probabilistic distributions, 
and cost-effectiveness results associated with 
selecting values at random from the distributions 
were entered in a Monte Carlo simulation of 
the model with 1000 runs. Cost-effectiveness 
acceptability curves were constructed to present the 
uncertainty of the ICER across different values of the 
decision thresholds or ceiling ratios that represents 
acceptable willingness-to-pay thresholds.
Results 
For the Hong Kong female population aged ≥40 in 
2009 (accounting for 1 961 000), the incremental 
total annualised costs, QALYs saved, and average 
cost-effectiveness ratio of different strategies 
were compared (Table). The optimal allocation of 
additional funding for breast cancer in descending 
order would be: (1) 25% reduction in waiting time 
for postoperative radiotherapy (US$5000/QALY); 
(2) enhanced home-based palliative care (US$7105/
QALY); (3) adjuvant sequential endocrine therapy 
(US$17 963/QALY); (4) targeted immunotherapy 
(US$62 092/QALY); and (5) mammography 
screening for women aged 40 to 69 years (US$72 576/
QALY). 
 In the probabilistic sensitivity analyses, the 
first three interventions were certain to be cost-
effective at the conventionally adopted threshold of 
US$50 000 per QALY saved (Figure not shown).
 Assuming an additional annual expenditure for 
breast cancer screening, diagnosis, and treatment 
in Hong Kong totalling about US$6.1 million, 
strategies including 25% reduction in waiting time 
for postoperative radiotherapy plus enhanced home-
based palliative care should be adopted, thereby 
yielding 902.1 additional QALYs overall. If an 
additional US$30 million were available, in addition 
to the above two strategies, sequential endocrine 
adjuvant therapy should also be adopted on a partial 
basis.
Discussion
Comparing cost-effectiveness of different strategies 
throughout the course of breast cancer provides a 
TABLE.  Generalised cost-effectiveness analysis for 1 961 100 Hong Kong Chinese women aged ≥40 years
Strategy Lifetime costs 
(million 2010 
US$)*
Lifetime 
quality-
adjusted life 
years (QALYs) 
saved*
Average cost-
effectiveness 
ratio (US$ per 
QALY saved)
Cumulative 
costs (million 
2010 US$)
Cumulative 
QALYs saved
25% reduction in waiting time for postoperative radiotherapy (for 
women with stage I-II breast cancer)
0.8 156.9 5000 0.8 156.9 
Enhanced home-based palliative care (for women with advanced 
cancer stages)
5.3 745.2 7105 6.1 902.1 
Providing an aromatase inhibitor for 2 to 3 years followed by 
tamoxifen (for women with postmenopausal oestrogen receptor 
positive cancer)
38.0 2118.0 17 963 44.1 3020.1 
1-year trastuzumab use (for women with HER2 over-expressed 
cancer)
448.1 7216.8 62 092 492.2 10 236.9 
Biennial mammography for women aged 40 to 69 years 4879.0 67 226.5 72 576 5371.3 77 463.5 
Incremental from biennial mammography for women aged 40 to 
69 years to women aged 40 to 79 years
721.7 3530.0 204 444 6092.9 80 993.4 
*	 Compared	with	the	status	quo	scenario,	which	is	the	current	standard	and	protocol	of	care	as	per	the	Hospital	Authority
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holistic value-for-money understanding of the full 
range of interventions, and thus enables rational 
prioritisation and coherent allocation of resources. 
The findings may also have implications for 
affordability of cancer medicines in the Hong Kong 
public health care system, and for societal values and 
financial consequences for patients and their families. 
 Of the additional interventions not currently 
covered in the public sector, mass mammography 
screening would be the least cost-effective, 
compared with a reduction in waiting time for 
postoperative radiotherapy, palliative services, 
or adjuvant endocrine and immunotherapy. This 
finding is consistent with two previous local studies: 
(1) a conventional cost-effectiveness analysis of 
mass mammography reported that the ICER was 
above that of broadly accepted thresholds,3 and (2) 
a GCEA of colorectal, cervical, and breast cancer 
screening in women suggested that routine regular 
mammography would be the least cost-effective 
compared with colonoscopy and cervical smears 
+/- human papillomavirus testing (ie the only other 
preventive screening programmes for common 
cancers in women).4 Underlying these findings is 
the relatively lower (albeit increasing)5 risk of breast 
cancer in Hong Kong Chinese women,3 compared 
with their western counterparts. A lower incidence 
would mean a lower prevalence of disease at the time 
of screening, which in turn affects the performance of 
the mammography when evaluated at the population 
level. Any potential benefit of earlier detection in 
a low-risk population would be outweighed by the 
corresponding potential risk/harm induced by over-
diagnosis, false positive screens, false reassurance, 
anxiety and psychological consequences.3 Screening 
the entire population would be very costly, where 
the benefits only accrue to a small number of 
women who develop cancer. The effectiveness of 
mammography screening would depend on the 
prevalence of undiagnosed disease. The effectiveness 
of cancer treatment would be largely similar across 
different populations. 
 A potential caveat was that the assumption of 
perfect adherence to the interventions does not fully 
reflect the inherent heterogeneities and complexities 
of disease type, service delivery, individual behaviour, 
and patient preferences. The optimised benefits 
projected in our model may not be completely 
realised. 
 Given the current disease pattern and age 
profile of patients in the Hong Kong Chinese female 
population, the most cost-effective interventions 
are those that ensure women receive the most-
intensive treatment and care after a diagnosis of 
breast cancer, rather than receive mammography 
screening at a younger age. Further studies are 
needed to understand how these decisions can be 
flexibly deployed to comply with various budgetary 
constraints, affordability of cancer medicines, and 
ethical considerations. Our results can further 
inform policy debates about resource allocation for 
service delivery regarding breast cancer prevention, 
diagnosis, treatment, and palliative care.
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